BioCryst to Report First Quarter 2025 Financial Results on May 5
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced it will release its first quarter 2025 financial results on Monday, May 5, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring management discussion of financial results and a corporate update.
Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato che pubblicherà i risultati finanziari del primo trimestre 2025 lunedì 5 maggio 2025. La società terrà una conference call e una webcast alle 8:30 a.m. ET dello stesso giorno, durante le quali la direzione discuterà i risultati finanziari e fornirà un aggiornamento aziendale.
Gli interessati potranno partecipare alla chiamata in diretta componendo il numero 1-844-481-2942 (nazionale) o 1-412-317-1866 (internazionale). Una webcast in diretta e una registrazione saranno disponibili nella sezione investitori sul sito www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el lunes 5 de mayo de 2025. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. ET del mismo día, en la que la dirección discutirá los resultados financieros y ofrecerá una actualización corporativa.
Los interesados pueden acceder a la llamada en vivo marcando 1-844-481-2942 (nacional) o 1-412-317-1866 (internacional). La transmisión en vivo y la repetición estarán disponibles en la sección de inversores en www.biocryst.com.
BioCryst Pharmaceuticals (나스닥: BCRX)는 2025년 5월 5일 월요일에 2025년 1분기 재무 결과를 발표할 예정입니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 경영진이 재무 결과와 기업 업데이트를 논의하는 컨퍼런스 콜 및 웹캐스트를 진행합니다.
관심 있는 분들은 국내 전화 1-844-481-2942 또는 국제 전화 1-412-317-1866으로 실시간 통화에 참여할 수 있습니다. 실시간 웹캐스트 및 녹화본은 www.biocryst.com 투자자 섹션에서 확인할 수 있습니다.
BioCryst Pharmaceuticals (Nasdaq : BCRX) a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le lundi 5 mai 2025. La société organisera une conférence téléphonique et un webcast à 8h30 ET le même jour, au cours desquels la direction discutera des résultats financiers et fera une mise à jour de l'entreprise.
Les personnes intéressées peuvent accéder à l'appel en direct en composant le 1-844-481-2942 (domestique) ou le 1-412-317-1866 (international). Un webcast en direct et un replay seront disponibles dans la section investisseurs sur www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat angekündigt, dass die Finanzergebnisse für das erste Quartal 2025 am Montag, den 5. Mai 2025, veröffentlicht werden. Das Unternehmen veranstaltet am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast, bei denen das Management die Finanzergebnisse bespricht und ein Unternehmensupdate gibt.
Interessierte können die Live-Schaltung unter der Nummer 1-844-481-2942 (national) oder 1-412-317-1866 (international) verfolgen. Ein Live-Webcast und eine Aufzeichnung sind im Investor-Bereich auf www.biocryst.com verfügbar.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When will BioCryst (BCRX) report Q1 2025 earnings?
How can investors join BioCryst's Q1 2025 earnings call?
Where can I find the replay of BCRX's Q1 2025 earnings webcast?
What time is BioCryst's Q1 2025 earnings call?
